Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists

Area of Science:

• Pharmacology
• Toxicology
• Carcinogenesis

Background:

• Dual-acting agonists targeting Peroxisome Proliferator-Activated Receptors alpha and gamma (PPARα+γ) show clinical potential but face development challenges.
• High attrition rates are linked to toxicity, specifically carcinogenic effects in the rat urothelium.
• Both PPARα and PPARγ activation are independently associated with rodent carcinogenesis.

Purpose of the Study:

• To propose a mode of action hypothesis for PPARα+γ agonist-induced urothelial carcinogenicity in rats.
• To investigate the combined role of receptor-mediated and off-target cytotoxic effects.
• To inform the development of safer dual-acting PPAR agonist compounds.

Main Methods:

• Literature review on PPARα and PPARγ roles in rodent carcinogenesis.
• Analysis of mode of action data for the PPARα+γ agonist ragaglitazar.
• Formulation of a hypothesis integrating receptor-mediated and cytotoxic effects.

Main Results:

• Urothelial cells coexpress PPARα and PPARγ, suggesting a plausible mechanism for agonist-induced carcinogenicity.
• A hypothesis combining exaggerated pharmacology (receptor-mediated) and off-target cytotoxicity is proposed.
• Ongoing laboratory investigations aim to validate this mode of action.

Conclusions:

• The proposed mode of action hypothesis provides a framework for understanding rat urothelial carcinogenicity of PPARα+γ agonists.
• Understanding this mechanism is crucial for assessing human relevance and developing safer drug candidates.
• Development of rapid screening assays is a key objective to facilitate future drug development.